FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an improved recombinant immunotoxin for the cells expressing mesothelin. Disclosed immunotoxin is a fused protein containing the antibody to mesothelin and Pseudomonas exotoxin fragment which is modified to reduce its immunogenicity and sensitivity to proteases. Immunotoxin can be used in the method for treatment of cancer overexpressing mesothelin.
EFFECT: invention provides high cytotoxicity of immunotoxin in relation to the cells expressing mesothelin.
21 cl, 9 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXOTOXIN A PSEUDOMONAS WITH LESS IMMUNOGENIC T-AND/OR B-CELL EPITHOPES | 2012 |
|
RU2627216C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
| SINGLE-CHAIN ANTIBODIES AND OTHER HETEROMULTIMERS | 2013 |
|
RU2644341C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| INTERFERON PRODRUG FOR CANCER TREATMENT | 2018 |
|
RU2788736C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
